Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers — ProBCG  

COVID 19 Vaccine Clinical Trial

Official title: Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers

Status Active, not recruiting

Clinical Trial Summary

The disease promoted by coronavirus (COVID-19) is caused by Severe Acute Respiratory Syndrome (SARS) caused by Coronavirus type 2 (CoV2), being the first cases identified in December 2019 in China after exposure to the animal market in Wuhan city, China. From the first case to the present day, the COVID-19 epidemic has been identified in 185 countries, with the notification of 2,666,154 cases and 186,144 deaths. In Brazil, more than 45,757 cases and 2,906 confirmed deaths by COVID-19 have been confirmed (Visualized on Apr 23 2020). In our country, to date, testing for COVID-19 occurs only in severe cases and few centers offer the service to health care workers, a population at high risk of infection. BCG is a vaccine produced from a live attenuated strain derived from a Mycobacterium bovis isolate and is widely used worldwide as a tuberculosis (TB) vaccine, but there are studies demonstrating non-specific immunotherapeutic mechanisms of this vaccine that signal a possible relationship with the lowest morbidity and mortality associated with COVID-19 infections worldwide. The present study aims to analyze the role of BCG in the prevention of SARS-CoV-2 infection and also in the occurrence of severe forms of COVID-19 in addition to evaluating the immune response mediated by this vaccine in voluntary health care workers.

Clinical Trial Description

Study detailed description can be seen on the protocol attached. ;

Related Conditions & MeSH terms

• COVID 19 Vaccine
• COVID-19

• NCT number: NCT04659941
• Study type: Interventional
• Source: Universidade Federal do Rio de Janeiro
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 1, 2020
• Completion date: April 1, 2024